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Objectives: To investigate cancer-specific mortality and other-cause mortality in
prostate cancer patients with nodal metastases.
Methods: The study included 411 patients treated with radical prostatectomy and
pelvic lymph node dissection for prostate cancer with lymph node metastases at 10
tertiary care centers between 1995 and 2014. Kaplan–Meier analyses were used to
assess cancer-specific mortality-free survival rates at 8 years’ follow up in the overall
population, and after stratifying patients according to clinical and pathological
parameters. Uni- and multivariable competing risk Cox regression analyses were used to
assess cancer-specific mortality and other-cause mortality. Finally, cumulative-incidence
plots were generated for cancer-specific mortality and other-cause mortality after
stratifying patients according to the number of positive lymph nodes and the median
age at surgery, according to the competing risks method.
Results: Men with prostate-specific antigen ≤40 ng/mL and those with one to three
positive lymph nodes showed higher cancer-specific mortality-free survival estimates as
compared with their counterparts with prostate-specific antigen >40 ng/mL and >3
metastatic lymph nodes, respectively (all P < 0.001). At multivariable Cox regression
analyses, preoperative prostate-specific antigen >40 ng/mL, >3 lymph node metastases
and pathological Gleason score 8–10 were all independent predictors of cancer-specific
mortality (all P-values ≤0.001). On competing risk analysis, when patients were stratified
according to the number of positive lymph nodes (namely, ≤3 vs >3), the 8-year cancer-
specific mortality rates were 27.4% versus 44.8% for patients aged <65 years, and 15.2%
versus 52.6% for patients aged ≥65 years, respectively.
Conclusions: Three positive lymph nodes represent the best prognostic cut-off in
node-positive prostate cancer patients. In those individuals with >3 positive lymph
nodes, the overall mortality rate is completely related to prostate cancer in young
patients.
Key words: cancer-specific mortality, competing risk analysis, lymph node metastases,
other-cause mortality, radical prostatectomy.
Introduction
In the PSA-era, approximately 10% of patients with clinically localized PCa after RP and
PLND have LNM at ﬁnal pathology.1–7 Unlike other types of cancer, in the current TNM
classiﬁcation8 all PCa patients with nodal metastases are classiﬁed in a single-risk group,9 and
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are considered as affected by systemic disease.10 However,
recent studies showed that outcomes of surgically-treated
patients with positive LNs are not invariably poor;6,7,11–14
indeed, patients with lower volumes of LNM have higher sur-
vival rates than those patients with a higher nodal burden.7,15
In this contest, contemporary retrospective analyses suggest
that RP in PCa patients with LNM might have a survival
beneﬁt after controlling for lymph node tumor burden.16,17
Indeed, despite the evidence supporting the use of adjuvant
aADT in patients with LNM,18 recent evidence suggests that
patients treated with aRT plus aADT had more favorable
CSM-free rates than patients treated with aADT alone.19,20
However, the optimal care of those patients is still debated.
Indeed, data investigating the competing risk of mortality in
node-positive PCa patients treated with adjuvant therapy are
still limited. Assessing these aspects would be important to
improve postoperative patients’ counseling, to help the physi-
cian in order to identify patients at high risk of dying as a
result of PCa and to plan the optimal postoperative treatment
strategy. To address this void, we assessed the long-term
CSM and OCM rate in a multi-institutional series of surgi-
cally-treated PCa patients with LNM, after stratifying patients
according to clinical and pathological characteristics.
Methods
Study population
We reviewed 4815 PCa patients treated with RP and PLND
between 1995 and 2014 at 10 tertiary European care centers.
In order to evaluate the survival outcomes of node-positive
PCa patients, we included 511 individuals (10.6%) with
LNM at ﬁnal pathology in our analysis. Among these 511
patients, 100 (19.6%) with incomplete clinical, pathological
and follow-up data, and with <10 LNs retrieved were
excluded, resulting in a ﬁnal population of 411 individuals.
All patients were preoperatively staged with CECT or BS or,
more recently, with 11C-choline PET/computed tomography
scan according to local protocol. Men with clinically local-
ized or locally advanced PCa were referred for surgery. No
patient had evidence of distant metastatic disease at preopera-
tive imaging; however, selected cases with clinically suspi-
cious of low-volume nodal involvement at preoperative
imaging (2.3%) were included. During the study period, sur-
gical procedures were carried out with a retropubic, laparo-
scopic or robot-assisted approach according to surgeon
preference by expert urologists who completed the learning
curve of the speciﬁc techniques. Routine PLND at the time
of RP in all the 10 centers was carried out in the presence of
high-risk PCa and intermediate-risk PCa with an estimated
risk for positive lymph nodes >5%; indeed, PLND was car-
ried out in low-risk PCa patients according to the surgeon’s
attitude. The template of the course of lymph node dissection
included the ﬁbrofatty tissue along the external iliac vein,
with the distal limit of the deep circumﬂex vein and the
femoral canal; proximally, the dissection was carried out up
to and including the bifurcation of the common iliac artery.
All ﬁbrofatty tissue within the obturator fossa was removed
to completely skeletonize the obturator nerve. The lateral
limit consisted of the pelvic sidewall, and the medial
dissection limit was deﬁned by perivesical fat.21 According to
the surgeon’s attitude, high-risk patients were submitted to
extended PLND including bilateral common iliac lymph
nodes, in selected cases, up to aortic bifurcation. Within all
centers, one experienced genitourinary pathologist reviewed
all surgical specimens.
Covariates and follow up
All patients had complete data including preoperative PSA,
biopsy Gleason score, pathological stage and Gleason score,
margin status, number of nodes removed, and number of pos-
itive nodes. All patients received postoperative therapy
including aADT alone or aRT in combination with aADT.
Regarding postoperative treatments, aADT consisted of hor-
mone deprivation therapy initiated within 90 days from RP.
Furthermore, aRT consisted of whole-pelvis irradiation tar-
geted to the prostatic and seminal vesicles bed (66 Gy) and
pelvic lymph nodes (54 Gy), including the bilateral obturator,
and external, internal and common iliac lymphatic chain, and
was started within 90 days of RP,17 according to local proto-
col and the treating physician’s preference.
Outcomes
The outcomes of the study were CSM, namely death due to
PCa and death due to any other cause (OCM). Vital status
and cause of death were identiﬁed from death certiﬁcates or
physician correspondence. On death certiﬁcates, PCa was
considered as the cause of death when it was registered as
the ﬁrst cause, otherwise OCM was considered as the cause
of death.
Statistical analysis
Median and interquartile ranges were reported for continuous
variables. Frequencies and proportions were reported for cate-
gorical variables. The Mann–Whitney U-test and v2-tests
were used to compare the statistical signiﬁcance of differ-
ences in medians and proportions, respectively. Our statistical
analyses consisted of several steps. First, Kaplan–Meier anal-
yses were used to assess CSM-free survival rates at 5- and 8-
year follow up in the overall population, and after stratifying
patients according to clinical and pathological parameters
(namely, preoperative PSA, number of positive LNs and
adjuvant treatments). The number of positive LNs and preop-
erative PSA were dichotomized according to the most infor-
mative cut-off predicting CSM-free survival. This was
obtained applying the v2-test for every possible cut-off value
and choosing the lowest P-value.
Second, uni- and multivariate logistic regression analysis
were used to test the association between preoperative
patients’ characteristics (namely, age, preoperative PSA; clini-
cal stage, biopsy Gleason score and number of LNs retrieved)
and the risk of >3 lymph node metastases after RP and
PLND. Third, uni- and multivariable competing risks Cox
regression models were used to identify predictors of CSM
and OCM. Covariates consisted of age at surgery, pathologi-
cal Gleason score, pathological stage, surgical margins status,
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number of LNs metastases and adjuvant therapies. Finally,
cumulative incidence plots were generated for CSM and
OCM according to the competing risks method, after stratify-
ing patients according to the number of LNs metastases and
median age at surgery.22 All statistical tests were carried out
using the R statistical package (R Foundation for Statistical
Computing, Vienna, Austria), with a two-sided signiﬁcance
level set at P < 0.05. The local institutional ethical commit-
tee approved the study (approval code STUD-OF by the S.
Orsola-Malpighi Hospital, IRB 11 September 2012).
Results
Overall, 411 node-positive PCa patients composed the ﬁnal
population. Overall, 352 (85.6%) patients underwent open
RP, whereas 16 (3.9%) had laparoscopic and 43 (10.5%) had
the robotic-assisted approach. Table 1 shows the baseline
characteristics of all patients included in the study, stratifying
patients according to the number of positive LNs at ﬁnal
pathology. The median number of lymph nodes removed was
15 (IQR 11–20). The median number of positive lymph
nodes was two (IQR 1–4): 308 (74.9%) patients showed ≤3
positive LNs, whereas 103 (25.1%) individuals had >3 posi-
tive LNs at ﬁnal pathology. Of all patients, 228 (55.5%) were
referred for aRT with aADT, whereas 183 (44.5%) received
aADT alone. When patients were stratiﬁed according to the
number of positive LNs (≤3 positive LNs vs >3 positive
LNs), signiﬁcant differences were recorded with regard to the
clinical and pathological Gleason score, number of LNs
retrieved, positive LNs, lymph node density and surgical
technique (all P ≤ 0.04; Table 1). At multivariable logistic
regression, the number of LNs retrieved resulted in the only
signiﬁcant predictor of more extended LNs involvement
(namely, >3 positive LNs; Table 2).
The median follow up for RP for survivors was 55 months
(IQR 34–86). During this period, there were 74 (18%) cancer-
speciﬁc deaths. Overall, the CSM-free survival estimates at 5-
and 8-year follow up were 84.5% and 71.1%, respectively
(Fig. 1). The best cut-off for PSA and LNM was 40 ng/mL
and three positive LNs, respectively. After stratifying patients
according to preoperative PSA value, men with PSA ≤20 ng/
mL and those with PSA between 21 and 40 ng/mL had higher
CSM-free survival estimates as compared with those patients
with PSA >40 ng/mL (87.5% and 84.8% vs 69.5% at 5-year
follow up, respectively; 72.6% and 84.8% vs 45.8% at 8-year
follow up, respectively, P < 0.001; Fig. 2). Considering
LNM, men with ≤3 positive LNs showed higher CSM-free
survival estimates as compared with those individuals with >3
positive LNs (87.1% vs 76.4% at 5-year follow up, respec-
tively; 77.1% vs 52.1% at 8-year follow up, respectively,
P < 0.001; Fig. 3). After stratifying patients according to
postoperative treatments, men submitted to aRT with aADT
tended to show better CSM-free survival estimates as com-
pared with those patients submitted to aADT alone, despite
any statistical signiﬁcance (88.0% vs 80.4% and 70.4 vs 70.8
at 5- and 8-year follow up, respectively; Fig. 4).
At multivariable Cox regression analyses (Table 3), pre-
operative PSA >40 ng/mL (HR 1.97), >3 positive LNs
(HR 2.16) and pathological Gleason score 8–10 (HR 2.07)
Table 1 Patient characteristics and descriptive statistics
Variable Overall
≤3 positive
LNs
>3 positive
LNs P-value
No. patients
(%)
411 (100) 308 (74.9) 103 (25.1) –
Age (years)
Median 65 65 65 0.8
IQR 60–70 61–70 60–70
PSA (ng/mL)
Median 15.5 15.3 16 0.4
IQR 8.2–30 8.1–28.1 8.8–36
PSA (ng/mL)
≤20 258 (62.8) 195 (63.3) 63 (61.2) 0.08
21–40 95 (23.1) 76 (24.7) 19 (18.4)
>40 58 (14.1) 37 (12) 21 (20.4)
Biopsy Gleason score (%)
<7 71 (17.4) 57 (18.6) 14 (13.7) 0.01
7 174 (42.5) 136 (44.3) 38 (37.3)
8–10 164 (40.1) 114 (37.1) 50 (49)
Clinical stage (%)
T1a 2 (0.5) 1 (0.3) 1 (1) 0.3
T1b 3 (0.7) 3 (1) 0 (0)
T1c 40 (9.7) 34 (11) 6 (5.8)
T2a 101 (24.6) 73 (23.7) 28 (27.2)
T2b 42 (10.2) 30 (9.7) 12 (11.7)
T2c 63 (15.3) 45 (14.6) 18 (17.5)
T3a 82 (20) 60 (19.4) 22 (21.4)
T3b 47 (11.4) 34 (11) 13 (12.6)
D’Amico risk group (%)
Low risk PCa 24 (5.8) 20 (6.5) 4 (3.9) 0.6
Intermediate
risk PCa
120 (29.2) 88 (28.6) 32 (31.1)
High risk PCa 267 (65) 200 (64.9) 67 (65)
Pathological Gleason score (%)
≤7 208 (50.6) 164 (53.2) 44 (42.7) 0.04
8–10 203 (49.4) 144 (46.8) 59 (57.3)
Pathological stage (%)
pT2 35 (8.5) 28 (9.1) 7 (6.8) 0.5
pT3a 100 (24.3) 79 (25.6) 21 (20.4)
pT3b 244 (59.4) 179 (25.1) 65 (63.1)
pT4 32 (7.8) 22 (7.1) 10 (9.7)
Surgical margins status (%)
Negative 157 (38.4) 120 (39) 39 (37.9) 0.5
Positive 252 (61.6) 188 (61) 68 (62.1)
No. LNs removed
Median 15 14 16 0.003
IQR 11–20 10–19 12–23
No. positive LNs
Median 2 1 6 <0.001
IQR 1–4 1–2 5–8
LN density
Median 12.5 10 40 <0.001
IQR 7.1–25 6.4–15.3 26.3–54.5
Years of surgery
1995–2000 37 (9) 29 (9.4) 8 (7.8) 0.4
2001–2005 88 (21.4) 66 (21.4) 22 (21.4)
2006–2010 188 (45.7) 126 (47.4) 42 (40.8)
2011–2014 98 (23.8) 67 (21.8) 32 (30.1)
Surgical technique
Open 352 (85.6) 273 (88.6) 79 (76.7) 0.01
Laparoscopic 16 (3.9) 10 (3.2) 6 (5.8)
Robotic 43 (10.5) 25 (8.1) 18 (17.5)
Adjuvant treatments
aADT alone 183 (44.5) 139 (45.1) 44 (42.7) 0.4
aRT with
aADT
228 (55.5) 169 (54.9) 59 (57.3)
Patients were stratified according to the number of positive LNs (namely,
men with ≤3 LNs and those with >3 LNs) at final pathology.
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were all independent predictors of CSM (all P-values
≤0.01).
To investigate the competing causes of mortality prevalent
in node-positive PCa, a competing risks analysis was carried
out to estimate the real risk of death from PCa rather than
any causes, considering the most informative threshold for
LNM and median age at surgery as confounders. When
patients were stratiﬁed according to LNM (namely, ≤3 vs
>3), the 8-year CSM rates were 27.4% versus 44.8% for
patients aged <65 years at surgery, and 15.2% versus 52.6%
for patients aged ≥65 years at surgery, respectively. Further-
more, considering individuals with ≤3 LNM, the 8-year
OCM rates were 16.2% and 23.2% for patients aged
<65 years and those aged ≥65 years at surgery, respectively.
Considering patients with >3 LNM, every cause of mortality
was due to PCa in men aged <65 years, whereas the 8-year
OCM rate was 2.6% in their older counterparts (Fig. 5).
Discussion
Despite node-positive PCa patients experiencing worse onco-
logical outcomes,7,11,15,23 previous studies showed that
patients with LNM represent a highly heterogeneous cate-
gory.7,11–13,15,24 Indeed several long-term data show excellent
cancer control outcomes for patients with LNM and with
favorable pathological aspects, suggesting the potential
overtreatment with indiscriminate use of postoperative hor-
monal therapies.25,26 However, the best treatment modality,
as well as the correct timing, remains unclear.
To address these issues, we collected one of the largest
cohorts of node-positive PCa patients submitted to RP and
PLND at multi-institutional European centers, and we carried
out a competing risk analysis to test the predictive value of
clinical and pathological variables on the risk of dying from
PCa rather than other causes. Such predictive tools could be
useful for many reasons: (i) to offer a prognostic stratiﬁcation
of node-positive patients after surgery for proper counseling
and follow-up planning; (ii) to investigate the real risk of
dying from PCa, according to age and the tumor’s character-
istics; and (iii) to propose selection criteria for future prospec-
tive randomized trials exploring the role of emerging
treatments in PCa patients with LNI.
Several ﬁndings of the present study were remarkable.
First, our analyses conﬁrmed that node-positive PCa patients
Table 2 Uni- and multivariate logistic regression analysis testing the
association between preoperative patients’ characteristics and the risk of
>3 lymph node metastases after RP in node-positive patients
Variables
Univariate Multivariate
OR (95% CI) P-value OR (95% CI) P-value
Age at
surgery (years)
0.99 (0.96–1.03) 0.7 1.00 (0.96–1.03) 0.9
Preoperative PSA 1.00 (0.98–1.01) 0.6 1.00 (0.99–1.01) 0.9
Clinical stage
T1 Reference Reference
T2 2.13 (0.90–5.04) 0.09 2.06 (0.86–4.97) 0.1
T3 2.02 (0.83–4.95) 0.1 1.76 (0.69–4.45) 0.2
Biopsy Gleason score
<7 Reference Reference
7 1.14 (0.57–2.26) 0.7 1.06 (0.52–2.16) 0.9
8–10 1.79 (0.91–3.50) 0.09 1.42 (0.70–2.89) 0.3
No. LNs retrieved 1.04 (1.01–1.06) 0.002 1.04 (1.01–1.07) 0.003
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Fig. 1 Kaplan–Meier curve showing CSM-free
survival rates in the overall patient population
(n = 411).
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after surgery showed favorable oncological outcomes, despite
LNM, as others authors previously reported.11,13,17 In this
contest, the 5- and 8-year CSM-free survival rates in the
overall population were 84.5% and 71.1%, respectively.
Second, even if in our population aRT was not an indepen-
dent predictor of better survival (P > 0.05), on multivariable
Cox analysis, those individuals treated with aRT with aADT
experienced slightly better CSM-free survival rates than those
referred for aADT alone (88% vs 80.4% at 5-year follow up,
respectively). Recent literature suggests a beneﬁcial impact of
aRT on CSM-free survival, and aRT could help reaching an
optimal local control improving cancer survival.19,20 A possi-
ble explanation of the present result could be found in the
relatively short follow-up period, and different timing, proto-
cols and indications of radiotherapy between single centers
through such a large timespan. It results in a potential
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Fig. 2 Kaplan–Meier curve showing CSM-free
survival rates in the overall patient population
(n = 411) after stratifying according to
preoperative PSA levels, (namely, PSA ≤20 ng/mL
vs PSA = 21–40 ng/mL vs PSA >40 ng/mL;
P < 0.001).
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Fig. 3 Kaplan–Meier curve showing CSM-free
survival rates in the overall patient population
(n = 411) after stratifying according to LNM,
(namely, LNM = 1–3 vs LNM >3; P < 0.001).
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underestimated beneﬁcial impact of radiation therapy on
cancer control in our population. Third, the present ﬁndings
conﬁrmed that the main clinical-pathological tumor character-
istics were independent predictors of CSM at multivariable
competing risk Cox regression analysis. For example, individ-
uals with preoperative PSA >40 ng/mL had a 1.97-fold
higher risk of dying from PCa as compared with those with a
preoperative PSA level of ≤20 ng/mL. Similarly, men with a
pathological Gleason score ≥8 had a 2.07-fold risk of experi-
encing unfavorable oncological outcomes as compared with
those patients with a pathological Gleason score of ≤7. Our
ﬁndings corroborate the results of previous reports and stress
the necessity to stratify node-positive PCa, maybe thanks to a
revision of the current TNM classiﬁcation.
More importantly, in contrast to previous reports that pro-
posed two positive LNs as a better prognostic cut-off, the
Adjuvant therapy status
%CSM free survival rates
(Cumulative events; No. at risk)
5 years 80.4
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Fig. 4 Kaplan–Meier curve showing CSM-free
survival rates in overall patient population
(n = 411) after stratifying according to
postoperative adjuvant treatments (namely, aRT
with aADT vs aADT alone; P = 0.6).
Table 3 Univariable and multivariable competing risks regression models predicting CSM and OCM in the overall population (n = 411)
Variables
CSM OCM
Univariable analyses Multivariable analyses Univariable analyses Multivariable analyses
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age at surgery (years) 0.99 (0.95–1.03) 0.5 0.99 (0.96–1.03) 0.8 0.99 (0.92–1.06) 0.8 0.97 (0.91–1.04) 0.4
Preoperative PSA (ng/mL)
≤20 Reference Reference Reference Reference
21–40 0.79 (0.41–1.51) 0.5 0.75 (0.38–1.49) 0.4 1.20 (0.38–3.78) 0.8 1.07 (0.32–3.53) 0.9
>40 2.29 (1.35–3.88) 0.002 1.97 (1.16–3.35) 0.01 1.22 (0.35–4.28) 0.8 1.3 (0.37–4.59) 0.7
Pathological stage
pT2–pT3a Reference Reference Reference Reference
pT3b–pT4 2.14 (1.20–3.80) 0.01 1.69 (0.91–3.15) 0.1 0.79 (0.30–2.10) 0.6 0.7 (0.25–1.97) 0.5
Pathological Gleason score
pGs ≤7 Reference Reference Reference Reference
pGs 8–10 2.5 (1.55–4.04) 0.0002 2.07 (1.24–3.47) 0.007 1.18 (0.46–3.02) 0.7 1.44 (0.51–4.08) 0.5
Surgical margins status
Negative Reference Reference Reference Reference
Positive 1.29 (0.79–2.10) 0.3 1.13 (0.70–1.85) 0.6 1.36 (0.51–3.64) 0.5 1.74 (0.61–4.99) 0.3
LNI
1–3 positive nodes Reference Reference Reference Reference
>3 positive nodes 2.6 (1.63–4.16) <0.001 2.16 (1.32–3.52) 0.002 0.63 (0.18–2.16) 0.5 0.6 (0.16–4.08) 0.4
Adjuvant treatment
aADT alone Reference Reference Reference Reference
aRT with aADT 0.92 (0.57–1.47) 0.7 0.78 (0.46–1.30) 0.3 0.42 (0.15–0.11) 0.1 0.34 (0.11–1.04) 0.06
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best cut-off of positive LNs in predicting CSM in our popula-
tion was three LNs.6,27 Observing the multivariable compet-
ing risk Cox regression, patients with >3 LNs involved by
PCa had a 2.16-fold risk of dying from PCa as compared
with those with ≤3 positive LNs. Accordingly, the Kaplan–
Maier curve showed that PCa patients with >3 positive LNs
experienced statistically signiﬁcant lower CSM-free survival
rates, as compared with those individuals with ≤3 positive
nodes. Thus, our data conﬁrmed that not all node-positive
PCa must be considered to be affected by systemic disease,
and that even those with >1 (but <4) positive lymph node
could experience good cancer control. As a consequence, RP
and PLND with appropriate postoperative multimodal treat-
ment could guarantee optimal oncological outcomes at long-
term follow up in those individuals with less aggressive
pathological characteristics.
Fourth, among our node-positive PCa patients at ﬁnal
pathological examination, the number of LNs retrieved was
found to be the only predictor of more extended LNs
involvement (namely, >3 positive LNs), whereas the other
preoperative characteristics (PSA, clinical stage and Gleason
score) did not (Table 2). As a consequence, in the PCa popu-
lation with a higher risk of LNs metastases, a more extended
PLND resulted in a proper selection of individuals with both
higher and lower nodal burdens, which would experience dif-
ferent survival outcomes.
Finally, we plotted CSM and OCM rates using a compet-
ing risks methodology, stratifying patients according to the
most informative threshold for LNI and median age at sur-
gery as confounders. In patients with ≤3 positive LNs, we
found that the proportion of individuals dying from PCa was
higher than the proportion of those dying from all other
causes, regardless of the age at surgery (Fig. 5). Conversely,
in patients with >3 positive LNs, the overall mortality rate
was completely related to PCa in men aged <65 years at sur-
gery, whereas not in those aged ≥65 years at surgery. Inter-
estingly, we observed that death from PCa was a competing
cause of mortality in PCa patients with ≤3 positive LNs,
regardless of age at surgery, and in older men with >3 LNs.
The main implications of these ﬁndings consist of proper
patient selection in order to identify which men are more
likely to die from PCa rather than other causes. Younger
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Fig. 5 Competing risks models showing 8-years CSM and OCM rates in 411 node-positive PCa patients referred for RP and PLND, and adjuvant treatments.
Patients were stratified according to the number of positive LNs (namely, ≤3 vs >3) and age at surgery (namely, <65 years vs ≥65 years). White area, alive; blue
area, OCM; yellow area, CSM.
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individuals, in particular those with a higher number of LNs
involvement, are at higher risk of succumbing to PCa, and
should be scheduled for more aggressive postoperative follow
up in order to guarantee an earlier detection of recurrence
and optimal salvage treatments options to reach cancer con-
trol. Indeed, despite older patients having a not negligible
risk of dying from other causes, a considerable proportion of
them could experience high PCa-related death; as a conse-
quence, age should not be taken into account to spare an
intensive follow-up schedule and aggressive treatments in
order to obtain better oncological control of disease.
Despite several strengths, the present study was not devoid
of limitations. First, our analyses were limited by their retro-
spective nature. For example, the exact timing of administra-
tion of postoperative therapies was left to the clinical
decision of each treating physician. Second, the study cov-
ered a long period of time. Diagnostic, grading and therapeu-
tic changes occurring over the past years might have
inﬂuenced our analysis. Furthermore, although the extent of
the nodal dissection was well standardized in all the treating
centers, variability in surgeons’ and pathologists’ attitudes, as
well as interindividual variability might have inﬂuenced the
accuracy of nodal staging; furthermore, the dissection tem-
plates could have varied among years in each center, accord-
ing to international guidelines modiﬁcations. Third, the
inclusion of patients coming from different referral centers
could have affected the results of our analyses, mainly due to
possible different surgical approaches and treatment behaviors
between single centres. Finally, a potential limitation of the
study was the lack of comorbidity data, which are required to
accurately predict OCM. Despite these limitations, our com-
peting risk analyses represent a reliable tool aimed at predict-
ing the long-term CSM rate after accounting for OCM rate,
in a large multi-institutional cohort of node-positive PCa, and
it could be useful to counsel patients correctly and to plan
proper postoperative follow up in order to guarantee an ear-
lier detection of recurrence and optimal salvage treatments
options to reach cancer control. Currently, all node-positive
PCa are classiﬁed in a single-risk group and are considered
as affected by systemic disease. However, these patients
might have optimal cancer control, especially when they
show an organ-conﬁned and well-differentiated disease with
low PSA and a low number of positive LNs.
In the present study population, three positive LNs repre-
sent the best prognostic cut-off: in patients with ≤3 positive
LNs, PCa is a competing cause of mortality, regardless of
age at surgery; in those individuals with >3 positive LNs, the
overall mortality rate is completely related to PCa in young
patients, whereas PCa remains a competing cause of mortality
in older patients. Indeed, despite older patients in the node-
positive PCa population having a not negligible risk of dying
from other causes, a considerable proportion of them could
experience PCa-related death. However, although RP and
PLND are not devoid of several side-effects, such aggressive
treatment options are curative in more than half of node-posi-
tive PCa patients, regardless of age and nodal metastases
volume. As a consequence, our risk stratiﬁcation of
node-positive PCa patients would help physicians to identify
patients with higher risk of dying from PCa, suggesting that
age should not be taken into account to spare more extensive,
multimodal treatment modalities in order to obtain optimal
cancer control.
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